Sequenom (SQNM) to Provide Coverage for Sequenom CMM MaterniT21 PLUS LDT
Tweet
Share
E-mailGet Alerts SQNM Hot Sheet
Join SI Premium – FREE
Sequenom, Inc. (Nasdaq: SQNM), announced that it has signed an agreement with U.S. health insurance provider Coventry Health Care National Network to provide coverage for the Sequenom Center for Molecular Medicine's (Sequenom CMM) MaterniT21 PLUS laboratory-developed test (LDT). The test detects certain fetal trisomies in women at increased risk of carrying a child with one of these chromosomal anomalies.
The agreement ensures that the 2.2 million members of the Coventry First Health PPO network will have coverage for Sequenom CMM's MaterniT21 PLUS testing service, with access to more than 5,000 hospitals and 500,000 health professionals in all 50 states, including the District of Columbia and Puerto Rico.
The agreement ensures that the 2.2 million members of the Coventry First Health PPO network will have coverage for Sequenom CMM's MaterniT21 PLUS testing service, with access to more than 5,000 hospitals and 500,000 health professionals in all 50 states, including the District of Columbia and Puerto Rico.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Boeing names Ryan Shedd as new SVP and controller
- Cytek faces $56M damages award in Beckman Coulter patent case
- Home Depot expands executive roles, grants $500K in restricted stock
Create E-mail Alert Related Categories
Corporate NewsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
